



**TABLE OF
CONTENTS**



TABLE OF CONTENTS

- SECTION ONE** - Names and complete addresses of the distributor and manufacturer of the new dietary ingredient.
- SECTION TWO** - Name of the new dietary ingredient.
- SECTION THREE** - Description of the new dietary ingredient with attachments.
- Attachment 3(A) - Specifications and Test Methods of Zinc Carnosine
- SECTION FOUR** - Level of the new dietary ingredient in the dietary supplement.
- SECTION FIVE** - The conditions of use recommended or suggested in the labeling of the dietary supplement.
- SECTION SIX** - History of use or other evidence of safety establishing that the dietary ingredient zinc carnosine as recommended in the labeling of dietary supplement products will be reasonably expected to be safe.
- Attachment 6(A) - Dietary Referenced Intakes chart from Institute of Medicine, Food and Nutrition Board report on micronutrients.
- Attachment 6(B) - Twinlab Phos Fuel 180 capsules and Endura High Magnesium Energy and Rehydration Drink.
- Attachment 6(C) - Discussion of discussion of the scientific and clinical documentation providing a basis for the safety of zinc carnosine provided by Robert A. DiSilvestro, Ph.D.
- Attachment 6(D) - Curriculum vitae of Robert A. DiSilvestro, Ph.D.
- Attachment 6(E)(1) - Applicability of zinc complex of L-carnosine for medical use. Biochemistry (Moscow) 65:961-968, 2000.

- Attachment 6(E)(2) - Metal complexes of carnosine. *Biochemistry (Moscow)* 65:928-927, 2000.
- Attachment 6(E)(3) - Interactions between carnosine, zinc and copper: implications for neuromodulation and neuroprotection. *Biochemistry (Moscow)* 65:807-816, 2000.
- Attachment 6(E)(4) - Endogenous mechanisms of neuroprotection: role of zinc, copper, and carnosine. *Brain Research* 852:56-61, 2000.
- Attachment 6(E)(5) - Carnosine: physiological properties and therapeutic potential. *Age and Ageing* 29:207-210, 2000.
- Attachment 6(E)(6) - Problems and perspectives in studying the biological role of carnosine. *Biochemistry (Moscow)* 65:751-756, 2000.
- Attachment 6(E)(7) - Hydrogen peroxide-mediated Cu,Zn-superoxide dismutase fragmentation: protection by carnosine, homocarnosine and anserine. *Biochimica et Biophysica Acta* 1472:651-657, 1999.
- Attachment 6(E)(8) - Polaprezinc protects gastric mucosal cells from noxious agents through antioxidant properties in vitro. *Alimentary Pharmacology & Therapeutics* 13:261-269, 1999.
- Attachment 6(E)(9) - Polaprezinc down-regulates proinflammatory cytokine-induced nuclear factor-kappaB activation and interleukin-8 expression in gastric epithelial cells. *Journal of Pharmacology & Experimental Therapeutics* 291:345-352, 1999.
- Attachment 6(E)(10) - Effect of polaprezinc (N-(3-aminopropionyl)-L-histidinato zinc), a novel antiulcer agent containing zinc, on cellular proliferation: role of insulin-like growth factor I. *Biochemical Pharmacology* 58:245-250, 1999.
- Attachment 6(E)(11) - Insulin-like growth factor I plays a role in gastric wound healing: evidence using a zinc derivative, polaprezinc, and an in vitro rabbit wound repair model. *Alimentary Pharmacology & Therapeutics* 12:1131-1138, 1998.

- Attachment 6(E)(12) - Toxicity of the novel anti-peptic ulcer agent polaprezinc in beagle dogs. *Arzneimittel Forschung (Drug Research)* 45:52-60, 1995.
- Attachment 6(E)(13) - Changes in tissue contents of zinc, copper and iron in rats and beagle dogs treated with polaprezinc. *Journal of Toxicological Sciences* 21:177-187, 1996.
- Attachment 6(E)(14) - High levels of dietary carnosine are associated with increased concentrations of carnosine and histidine in rat soleus muscle *Journal of Nutrition* 131:287-90, 2001.
- Attachment 6(E)(15) - Tissue distribution of polaprezinc in rats determined by the double tracer method. *Journal of Pharmaceutical & Biomedical Analysis* 19:453-461, 1999.
- Attachment 6(E)(16) - Effects of polaprezinc on lipid peroxidation, neutrophil accumulation, and TNF-alpha expression in rats with aspirin-induced gastric mucosal injury. *Digestive Diseases & Sciences* 46:845-851, 2001.
- Attachment 6(E)(17) - Irritant action of monochloramine in rat stomachs: effects of zinc L-carnosine (polaprezinc). *General Pharmacology* 29:713-718, 1997.
- Attachment 6(E)(18) - Mucosal ulcerogenic action of monochloramine in rat stomachs: effects of polaprezinc and sucralfate. *Digestive Diseases & Sciences* 42:2156-2163, 1997.
- Attachment 6(E)(19) - Clinical Evaluation of Z-103 on Gastric Ulcer. *Japanese Pharmacology & Therapeutics* 20, 1992.
- Attachment 6(E)(20) - Clinical Evaluation of Z-103 on Gastric Ulcer-A Multicenter Double-Blind Comparative Study with Cetraxate Hydrochloride. *Japanese Pharmacology & Therapeutics* 20, 1992.
- Attachment 6(E)(21) - Clinical Evaluation of Z-103 in the Treatment of Gastric Ulcer-A Multicenter Double-Blind Dose Finding Study. *Japanese Pharmacology & Therapeutics* 20:181-197, 1992.

- Attachment 6(E)(22) - Clinical Evaluation of Z-103 on Gastric Ulcer-Preliminary Evaluation for Dosage. Japanese Pharmacology & Therapeutics 20, 1992.
- Attachment 6(E)(23) - Clinical Study of Z-103-Clinical Effects on Gastric Ulcer and Influence on Endocrine Function. Japanese Pharmacology & Therapeutics 20(1):245-254, 1992.
- Attachment 6(E)(24) - Clinical Evaluation of Z-103 on Gastric Ulcer. Japanese Pharmacology & Therapeutics 20, 1992.
- Attachment 6(E)(25) - Clinical Evaluation of Z-103 on Gastric Ulcer-Results of phase III general clinical trial. Japanese Pharmacology & Therapeutics 20, 1992.
- Attachment 6(E)(26) - Clinical Phase I Study of Z-103. Clinical Pharmacology 20(1):149-163, 1992.
- Attachment 6(E)(27) - Toxic appearance and changes of zinc and copper content in rats by long-term oral dosing of Z-103. Biomed. Res. Trace Elem 4(2):61-2, 1993.
- Attachment 6(E)(28) - Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. Journal of Viral Hepatitis 8:367-371, 2001.

SECTION SEVEN - Summary